pancreatic adenocarcinoma
Oncology · 2018–2024
3decisions
1medicine
3carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| irinotecan (nanoliposomal) First-line treatment of metastatic pancreatic adenocarcinoma (mPAC) in combination with oxaliplatin, 5-fluorouracil (5-FU) and folinic acid/leucovorin (LV) as… | Mar 2024 | Not recommended | 3 individuals Australian Pancreatic Cancer Foundation · Rare Cancers Australia |
| irinotecan (nanoliposomal) First-line treatment of metastatic pancreatic adenocarcinoma in combination with oxaliplatin, 5-fluorouracil, and folinic acid/leucovorin (NALIRIFOX regimen). | Nov 2024 | Not recommended | 1 individuals Australian Pancreatic Cancer Foundation · Pancare Foundation · Rare Cancers Australia · Medical Oncology Group |
| irinotecan (nanoliposomal) Treatment of patients with metastatic pancreatic adenocarcinoma who have previously failed gemcitabine-based therapy, in combination with 5-fluorouracil and… | Mar 2018 | Not recommended | 2 individuals Medical Oncology Group |
Who spoke
Australian Pancreatic Cancer Foundation · Rare Cancers Australia · Medical Oncology Group · Pancare Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.